Resources
9 Results (showing 1 - 9)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 4/26/2021 (updated 4/10/2024)
A Protocol Using Empirically Supported Behavioral Treatments for People with Psychoactive Stimulant Use Disorders
Posted 12/23/2020 (updated 4/4/2024)
This toolkit is designed primarily for substance use and child welfare practitioners, as well as other service providers and health system planners who offer services to, or design services with, pregnant women and new mothers who use substances. Much is changing in the substance use and child welfare fields to bring forth approaches that are culturally safe, trauma informed, harm reduction-oriented and participant-driven. This toolkit highlights these advances and invites people working in both systems to think about how we can continue to improve our work, in partnership with the women who use these services.
Posted 10/23/2020 (updated 4/3/2024)
The American Society of Addiction Medicine (ASAM) developed this National Practice Guideline for the Treatment of Opioid Use Disorder to provide information on evidence-based treatment of opioid use disorder.
Posted 7/22/2020 (updated 3/28/2024)
The Data Sharing among Criminal Justice & Behavioral Health Partners: Addressing Data Sharing Agreements & Confidentiality Concerns Webinar was held June 24, 2020. The resources from this webinar are shared below.
Posted 1/17/2023 (updated 3/27/2024)
The Consolidated Appropriations Act of 2023 removed the federal requirement for providers to have an X-waiver to prescribe medications for the treatment of OUD. The act amended the Controlled Substances Act. Depending on state law, practitioners who have a current DEA registration with Schedule III authority will be able to prescribe buprenorphine for OUD starting now.
Posted 8/2/2022 (updated 3/27/2024)
Innovative at their inception three decades ago, drug courts confront a practical and ethical obligation to reimagine some core practices and assumptions. A shifting legal and public health landscape means, for example, increased scrutiny of the courts’ focus on abstinence and mandated treatment, and the use of jail. This publication argues the most effective way for drug courts to evolve is by integrating the practices and principles of harm reduction
Posted 3/15/2022 (updated 3/27/2024)
This TIP reviews three Food and Drug Administration-approved medications for opioid use disorder treatment—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support people in recovery.
Posted 2/9/2022 (updated 3/26/2024)
Summary of innovation abstracts that were presented at the National Academy of Medicine’s recent Stigma of Addiction Summit.
Posted 10/3/2019 (updated 3/25/2024)
Focus Group / Key informant interview sample questions